Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Deferred Revenue (2016 - 2025)

Guided Therapeutics' Current Deferred Revenue history spans 16 years, with the latest figure at $189000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 77.74% to $189000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $189000.0, a 77.74% decrease, with the full-year FY2025 number at $189000.0, down 77.74% from a year prior.
  • Current Deferred Revenue hit $189000.0 in Q4 2025 for Guided Therapeutics, down from $689318.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for GTHP hit a ceiling of $278.0 million in Q3 2021 and a floor of $62000.0 in Q1 2021.
  • Historically, Current Deferred Revenue has averaged $14.4 million across 5 years, with a median of $511050.5 in 2022.
  • Biggest five-year swings in Current Deferred Revenue: soared 661804.76% in 2021 and later tumbled 99.82% in 2022.
  • Tracing GTHP's Current Deferred Revenue over 5 years: stood at $337315.0 in 2021, then surged by 50.93% to $509101.0 in 2022, then dropped by 16.67% to $424225.0 in 2023, then surged by 100.11% to $848917.0 in 2024, then crashed by 77.74% to $189000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for GTHP at $189000.0 in Q4 2025, $689318.0 in Q3 2025, and $679318.0 in Q2 2025.